Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Analysts

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has been given a consensus recommendation of “Moderate Buy” by the twenty-seven ratings firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $490.9604.

A number of research analysts recently commented on the stock. Leerink Partners lowered their price target on shares of Alnylam Pharmaceuticals from $370.00 to $351.00 and set a “market perform” rating for the company in a report on Monday, December 15th. Truist Financial reduced their target price on shares of Alnylam Pharmaceuticals from $535.00 to $530.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Barclays raised their target price on shares of Alnylam Pharmaceuticals from $460.00 to $527.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Wall Street Zen upgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 10th. Finally, JPMorgan Chase & Co. reduced their price objective on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating on the stock in a research report on Monday, October 13th.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Needham published a bullish forecast expecting strong price appreciation for ALNY, citing upside from the company’s longer-term growth plan. Needham & Company LLC Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
• Neutral Sentiment: A Yahoo Finance piece examined Alnylam’s valuation in light of the newly unveiled Alnylam 2030 plan — useful context for investors weighing the company’s premium valuation against projected revenue/profitability milestones. A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
• Neutral Sentiment: CEO Yvonne Greenstreet discussed development priorities and the path to profitability in a media interview — helpful for understanding management’s messaging but not new data. Alnylam Pharmaceuticals CEO on development goals, profitability
• Negative Sentiment: Bank of America issued a pessimistic forecast for ALNY, adding downward analyst pressure after the guidance/2030 announcement. Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price
• Negative Sentiment: Market reaction: a Yahoo report noted ALNY slid sharply after the ambitious 2026 guidance and 2030 plan reveal — indicates investor concern about near-term targets or execution risk. Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal
• Negative Sentiment: Multiple insiders (including CEO Yvonne Greenstreet and several EVPs) disclosed sizable stock sales on Jan. 12–13, reducing ownership by ~4–11% in individual cases — typically viewed as a negative signal or a source of additional selling pressure. SEC filing example: SEC filing — Yvonne Greenstreet sale

Insider Transactions at Alnylam Pharmaceuticals

In related news, EVP Tolga Tanguler sold 1,510 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $547,933.70. Following the completion of the sale, the executive vice president directly owned 29,728 shares of the company’s stock, valued at approximately $10,787,399.36. This trade represents a 4.83% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $362.87, for a total value of $1,008,778.60. Following the completion of the transaction, the executive vice president directly owned 57,465 shares in the company, valued at $20,852,324.55. This trade represents a 4.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders sold 56,955 shares of company stock valued at $24,072,733. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Northwest Wealth Management LLC purchased a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $225,000. Eastern Bank bought a new stake in Alnylam Pharmaceuticals during the 4th quarter valued at $42,000. USA Financial Formulas purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $169,000. Kaufman Rossin Wealth LLC grew its position in shares of Alnylam Pharmaceuticals by 55.1% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 749 shares of the biopharmaceutical company’s stock worth $298,000 after buying an additional 266 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its position in shares of Alnylam Pharmaceuticals by 13.9% during the 4th quarter. Exchange Traded Concepts LLC now owns 2,361 shares of the biopharmaceutical company’s stock worth $939,000 after buying an additional 288 shares in the last quarter. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $366.86 on Thursday. Alnylam Pharmaceuticals has a 52-week low of $205.87 and a 52-week high of $495.55. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 4.45. The firm’s fifty day moving average is $422.03 and its 200 day moving average is $421.56. The company has a market cap of $48.47 billion, a price-to-earnings ratio of 1,528.58 and a beta of 0.32.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.